NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Changed after they new the results of the 2015 efficacy IA.

Sorry pal, that NEBO was still blinded to individual patient level data did not mean they did not top line numbers. You can even find BP's publisjing top line numbers while still formally blinded. For example

Positive results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's Imfinzi (durvalumab) in combination with standard-of-care FLOT neoadjuvant chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel given before surgery) demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy alone for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.

These results will be presented today at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain (abstract #LBA73).

Treatment with Imfinzi plus neoadjuvant FLOT chemotherapy resulted in a pCR rate of 19% versus 7% for patients treated with neoadjuvant chemotherapy alone as assessed by blinded independent central review (BICR) (difference in pCR rate 12%; odds ratio [OR] 3.08; p<0.00001). The rate of either complete or near-complete responses was 27% with the Imfinzi combination and 14% with neoadjuvant chemotherapy alone.

The trial, which is assessing Imfinzi in combination with FLOT chemotherapy as a perioperative treatment (before and after surgery), will continue as planned to assess the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) to which the trial team, investigators and participants remain blinded.

You guys can keep tossing the straw argument that all that matters is it being prior to unbinding all you want. The key is that it s not driven by information from the trial. And the IA was huge information.